N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide

生物活性靶点体外研究 N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide 试剂级价格

CAS号:392721-37-8
英文名:N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide
中文名:N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide
CBNumber:CB21845028
分子式:C11H9ClF3NO2
分子量:279.64
MOL File:392721-37-8.mol

N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide化学性质

沸点 :394.2±42.0 °C(Predicted)
密度 :1.411±0.06 g/cm3(Predicted)
储存条件 :room temp
溶解度 :DMSO: >10mg/mL
形态 :powder
酸度系数(pKa) :10.76±0.46(Predicted)
颜色 :white to off-white
稳定性 :Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.

安全信息

危险品标志 :Xn
危险类别码 :22
WGK Germany :3

N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide性质、用途与生产工艺

生物活性 Fasentin 是有效的葡萄糖摄取抑制剂，可抑制 GLUT-1/GLUT-4 转运蛋白。Fasentin 优先抑制 GLUT4 (IC50=68 μM)。Fasentin 是死亡受体刺激 (FAS) 敏化剂，可敏化细胞对 FAS 诱导的细胞死亡。Fasentin 也是诱导肿瘤坏死因子 (TNF) 凋亡配体的敏化剂。Fasentin 阻断癌细胞系中的葡萄糖摄取，并具有抗血管生成活性。
靶点

GLUT4

68 μM (IC ₅₀ )

GLUT1

体外研究

Fasentin (0.1-1000 μM; 72 hours) inhibits endothelial, tumour and fibroblast cell growth without inducing cell death.
Fasentin (25-100 μM; 16-24 hours) induces a cell cycle arrest in G0/G1 phase and reduces the cell number in S phase in a dose-dependent manner.
Fasentin (50 μM; 16 hours) alters expression of genes associated with glucose deprivation such as AspSyn and PCK-2.
Fasentin (15, 30, 80 μM; pretreatment 1 hour) induces glucose deprivation, partially blocks glucose uptake in PPC-1, DU145, and U937 cells.
Fasentin (100 μM; 16 hours) does not affect the migratory capability of endothelial cells.
Fasentin (25-100 μM; 16 hours) lowers levels of phospho-ERK in HMECs, indicating a partial inhibition on the ERK signalling pathway, even though the effect is not statistically significant. Fasentin does not inhibit the tyrosine kinase activity of VEGFR2.
Fasentin interacts with a unique site in the intracellular channel of GLUT1.

Cell Viability Assay

Cell Line:	Three types of endothelial cells ECs (HMEC, human microvascular endothelial cells; HUVEC, human umbilical vein endothelial cells; and BAEC, bovine aortic endothelial cells), three human tumour cell lines (MDA-MB-231 and MCF7 breast carcinoma cells, and HeLa cervix adenocarcinoma cells), and human gingival fibroblasts (HGF)
Concentration:	0.1, 1, 10, 100, 1000 μM
Incubation Time:	72 hours
Result:	Inhibited endothelial, tumour and fibroblast cell growth (IC ₅₀ =26.3-111.2 μM) without inducing cell death.

Cell Cycle Analysis

Cell Line:	HMECs
Concentration:	25, 50, 100 μM
Incubation Time:	16, 24 hours
Result:	Induced a cell cycle arrest in G0/G1 phase and reduced the cell number in S phase in a dose-dependent manner. Did not increase the subG1 population.

RT-PCR

Cell Line:	PPC-1 cells ^[2]
Concentration:	50 μM
Incubation Time:	16 hours
Result:	Altered expression of genes associated with glucose deprivation such as AspSyn and PCK-2 not FLIP mRNA expression.